Thomas Stankovich, Chief Financial Officer at ReShape Lifesciences Inc. (RSLS), sold 435 shares at $0.27 ($386) on 2023-10-25, disclosed to the SEC on 2023-11-08.
Open-market sale of $386 RSLS by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.43 | 108 | $154 | 40.0% |
| 2 | $1.42 | 39 | $55 | 14.3% |
| 3 | $0.89 | 118 | $105 | 27.2% |
| 4 | $0.93 | 39 | $36 | 9.4% |
| 5 | $0.27 | 131 | $35 | 9.2% |
| Total | $0.89 avg | 435 |
| $386 |
| 100% |
| Filing → |
| RSLS | SELL | 2023-07-06 | $746 | — | Filing → |
| RSLS | BUY | 2023-07-06 | $27K | — | Filing → |
| RSLS | SELL | 2023-03-07 | $4K | — | Filing → |